Longboard Pharmaceuticals, Inc. Net Income (Loss), Including Portion Attributable to Noncontrolling Interest
Longboard Pharmaceuticals, Inc. reported Net Income (Loss), Including Portion Attributable to Noncontrolling Interest of -$61.31 million for the 9-month period ending 2024-09-30, per its 10-Q filed 2024-11-07.
Financial Statements › Income Statement › Net Income
us-gaap:ProfitLoss · last filed 2024-11-07
- Longboard Pharmaceuticals, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2024-09-30 was -$24.54M.
- Longboard Pharmaceuticals, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2024-06-30 was -$21.79M.
- Longboard Pharmaceuticals, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2024-03-31 was -$14.99M.
- Longboard Pharmaceuticals, Inc. net income (loss), including portion attributable to noncontrolling interest for the quarter ending 2023-12-31 was -$15.03M.
- Longboard Pharmaceuticals, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2023 was -$54.42M.
- Longboard Pharmaceuticals, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2022 was -$43.95M.
- Longboard Pharmaceuticals, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2021 was -$27.80M.
- Longboard Pharmaceuticals, Inc. net income (loss), including portion attributable to noncontrolling interest for fiscal 2020 was -$14.40M.
| Period end | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 3 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 6 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 9 month | Net Income (Loss), Including Portion Attributable to Noncontrolling Interest 12 month |
|---|---|---|---|---|
| 2024-09-30 | -$24.54M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$46.33M derived: sum of 2 quarters · filed 2024-11-07 | -$61.31M 10-Q · filed 2024-11-07 | -$76.34M derived: sum of 4 quarters · filed 2024-11-07 |
| 2024-06-30 | -$21.79M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | -$36.77M 10-Q · filed 2024-08-01 | -$51.80M derived: sum of 3 quarters · filed 2024-08-01 | -$64.74M derived: sum of 4 quarters · filed 2024-11-07 |
| 2024-03-31 | -$14.99M 10-Q · filed 2024-05-02 | -$30.02M derived: sum of 2 quarters · filed 2024-05-02 | -$42.95M derived: sum of 3 quarters · filed 2024-11-07 | -$57.95M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-12-31 | -$15.03M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | -$27.97M derived: sum of 2 quarters · filed 2024-11-07 | -$42.97M derived: sum of 3 quarters · filed 2024-11-07 | -$54.42M 10-K · filed 2024-03-12 |
| 2023-09-30 | -$12.93M derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-07 | -$27.93M derived: sum of 2 quarters · filed 2024-11-07 | -$39.39M 10-Q · filed 2024-11-07 | -$50.73M derived: sum of 4 quarters · filed 2024-11-07 |
| 2023-06-30 | -$15.00M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | -$26.45M 10-Q · filed 2024-08-01 | -$37.80M derived: sum of 3 quarters · filed 2024-08-01 | -$49.40M derived: sum of 4 quarters · filed 2024-08-01 |
| 2023-03-31 | -$11.46M 10-Q · filed 2024-05-02 | -$22.80M derived: sum of 2 quarters · filed 2024-05-02 | -$34.40M derived: sum of 3 quarters · filed 2024-05-02 | -$45.80M derived: sum of 4 quarters · filed 2024-05-02 |
| 2022-12-31 | -$11.35M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | -$22.94M derived: sum of 2 quarters · filed 2024-03-12 | -$34.35M derived: sum of 3 quarters · filed 2024-03-12 | -$43.95M 10-K · filed 2024-03-12 |
| 2022-09-30 | -$11.60M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-02 | -$23.00M derived: sum of 2 quarters · filed 2023-11-02 | -$32.60M 10-Q · filed 2023-11-02 | -$41.37M derived: sum of 4 quarters · filed 2023-11-02 |
| 2022-06-30 | -$11.41M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-03 | -$21.00M 10-Q · filed 2023-08-03 | -$29.78M derived: sum of 3 quarters · filed 2023-08-03 | -$36.12M derived: sum of 4 quarters · filed 2023-08-03 |
| 2022-03-31 | -$9.60M 10-Q · filed 2023-05-09 | -$18.37M derived: sum of 2 quarters · filed 2023-05-09 | -$24.71M derived: sum of 3 quarters · filed 2023-05-09 | -$31.70M derived: sum of 4 quarters · filed 2023-05-09 |
| 2021-12-31 | -$8.77M derived: 10-K 12 month − 10-Q 9 month · filed 2023-03-02 | -$15.12M derived: sum of 2 quarters · filed 2023-03-02 | -$22.10M derived: sum of 3 quarters · filed 2023-03-02 | -$27.80M 10-K · filed 2023-03-02 |
| 2021-09-30 | -$6.34M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | -$13.32M derived: sum of 2 quarters · filed 2022-11-03 | -$19.02M 10-Q · filed 2022-11-03 | |
| 2021-06-30 | -$6.98M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-04 | -$12.68M 10-Q · filed 2022-08-04 | ||
| 2021-03-31 | -$5.70M 10-Q · filed 2022-05-05 | |||
| 2020-12-31 | -$14.40M 10-K · filed 2022-03-03 | |||
| 2020-09-30 | -$2.55M derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | -$4.12M derived: sum of 2 quarters · filed 2021-11-04 | -$4.29M 10-Q · filed 2021-11-04 | |
| 2020-06-30 | -$1.57M derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-09 | -$1.74M 10-Q · filed 2021-08-09 | ||
| 2020-03-31 | -$174.00K 10-Q · filed 2021-05-10 |